|View printer-friendly version|
|Data from CytomX's Probody™ Pipeline to be Presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics|
Therapeutics developed with CytomX's Probody platform are designed to be active in the tumor while sparing healthy tissue. This design is intended to avoid the toxicities that have been seen with many potent cancer therapies. CytomX's preclinical pipeline of wholly-owned and partnered programs includes Probody cancer immunotherapies, Probody drug conjugates and Probody bispecifics.
Investor Event and Webcast
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/data-from-cytomxs-probody-pipeline-to-be-presented-at-the-2015-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-300166141.html